More Frequent Dialysis (>3 Treatments Per Week)

Study of Clinical Outcomes of More Frequent Hemodialysis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00575497

Acronym

MFD

Enrollment

Registered

2007-12-18

Start date

2005-01-31

Completion date

2012-08-07

Last updated

2019-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease, Chronic Kidney Disease

Keywords

Hemodialysis, Adequacy, Frequency

Brief summary

The study compares the benefits of short daily hemodialysis six days a week, nocturnal (night time) hemodialysis six days a week, every other day and every other night hemodialysis to traditional three days a week hemodialysis.The hypothesis is that increasing hemodialysis treatment time and/or frequency will improve outcomes.

Interventions

PROCEDUREMore frequent hemodialysis

Six Day per week short daily hemodialysis

PROCEDUREConventional Hemodialysis

3 days per week short daily hemodialysis

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Stable vascular access, i.e., lack of needling difficulties and stable flow rates. Accesses will include fistulae, grafts, catheters and ports. * 18 years of age. * History of compliance with a dialysis treatment schedule, or if a new patient, express a willingness to be compliant with a treatment schedule. * Plan to continue care and follow-up at the investigational site. * Able to sign the informed consent and other relevant documents.

Exclusion criteria

* History of poor compliance with thrice (or twice) weekly dialysis schedules as manifested by more than three unexplained missed treatments in the past six (6) months. * Pregnancy. * Intravenous drug abuser. * Expects to receive a transplant or transfer to another facility within six months of entering the study.

Design outcomes

Primary

Measure	Time frame
Hospitalization days per year	Ongoing

Secondary

Measure	Time frame
Nutritional Status measured by Subjective Global Assessment	Ongoing
Anemia, measured by erythropoetin dose	Ongoing
Control of hypertension, as measured by number of antihypertensive tablets taken per day	Ongoing
Control of hyperphosphatemia, as measured by number of phosphate binder tablets taken per day	Ongoing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026